Medical News

Early Treatment of HIV-Positive Infants Might Allow Later Therapy Interruptions, Study Shows

August 23, 2013

According to results from the long-running CHER trial published online in The Lancet, HIV-positive "[c]hildren who began an immediate course of [antiretroviral (ARV)] drugs were able to interrupt their treatment, giving them a break from the powerful, potentially toxic drugs," Agence France-Presse/GlobalPost reports (8/21). "'Breaks' from HIV treatment could help reduce drug resistance in children, who have fewer ARV treatment options than adults, and reduce side effects in the long term, according to Dr. Mark Cotton, the study's lead author and Tygerburg Hospital's head of pediatric infectious diseases," Health-e News notes.

Conducted in South Africa "among 377 HIV-positive infants, the randomized controlled clinical trial tested whether babies who started ARVs at about two months old could safely interrupt their treatment with careful monitoring," the news service writes, adding, "Babies in the study were placed on ARVs and then stopped at either 10 months or two years. Babies were restarted on treatment if their CD4 counts fell to less than 1000." Health-e continues, "At the end of the trial, about half of the babies who had interrupted treatment were still well enough to remain off ARVs" (Gonzalez, 8/22). While the findings renew "hopes ... that patients could get a temporary holiday from AIDS drugs," Robert Colebunders of the Institute of Tropical Medicine in Belgium and Victor Musiime of Makerere University College of Health Sciences in Uganda cautioned against the practice in an accompanying commentary, AFP notes, adding, "Treatment interruption is a risky option in poor countries which lack laboratory facilities to monitor levels of CD4 immune cells, they said" (8/21).

Back to other news for August 2013

This information was reprinted from with permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Global Health Policy Report, search the archives, and sign up for email delivery. © Henry J. Kaiser Family Foundation. All rights reserved.

This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily Global Health Policy Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.

No comments have been made.

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.